Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 19, 2017
What is the competitive landscape for AMGEN, and when can generic versions of AMGEN drugs launch?
AMGEN has two approved drugs.| Patents: | 9 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-003 | Mar 8, 2004 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-001 | Mar 8, 2004 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-002 | Mar 8, 2004 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-001 | Mar 8, 2004 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-003 | Mar 8, 2004 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-002 | Mar 8, 2004 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-003 | Mar 8, 2004 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-002 | Mar 8, 2004 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-001 | Mar 8, 2004 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
cinacalcet hydrochloride | Tablets | 30 mg, 60 mg and 90mg | SENSIPAR | 3/10/2008 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5,391,210 | Abrasive article | ► Subscribe | |||||||||||||||||||||||||||
| 5,962,314 | Calcium receptor-active molecules | ► Subscribe | |||||||||||||||||||||||||||
| 5,858,684 | Method of screening calcium receptor-active molecules | ► Subscribe | |||||||||||||||||||||||||||
| 5,763,569 | Calcium receptor-active molecules | ► Subscribe | |||||||||||||||||||||||||||
| 5,688,938 | Calcium receptor-active molecules | ► Subscribe | |||||||||||||||||||||||||||
| 6,211,244 | Calcium receptor-active compounds | ► Subscribe | |||||||||||||||||||||||||||
| 6,001,884 | Calcium receptor-active molecules | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China | 1534016 | ► Subscribe | |||||||||||||||||||||||||||
| African Regional IP Organization (ARIPO) | 1907 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | H09281109 | ► Subscribe | |||||||||||||||||||||||||||
| Georgia, Republic of | P20084467 | ► Subscribe | |||||||||||||||||||||||||||
| Singapore | 125229 | ► Subscribe | |||||||||||||||||||||||||||
| Australia | 675891 | ► Subscribe | |||||||||||||||||||||||||||
| Eurasian Patent Organization | 200600320 | ► Subscribe | |||||||||||||||||||||||||||
| Mexico | PA06002616 | ► Subscribe | |||||||||||||||||||||||||||
| Taiwan | 568896 | ► Subscribe | |||||||||||||||||||||||||||
| Israel | 173959 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0199 | Netherlands | ► Subscribe | |||||||||||||||||||||||||||
| C0029 | France | ► Subscribe | PRODUCT NAME: CINACALCET; REGISTRATION NO/DATE: EU/01/04/292/001-012 20041022 | ||||||||||||||||||||||||||
| 1203761/01 | Switzerland | ► Subscribe | PRODUCT NAME: CINACALCETUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56965 27.10.2004 | ||||||||||||||||||||||||||
| 2005 00027 | Denmark | ► Subscribe | |||||||||||||||||||||||||||
| C020/2005 | Ireland | ► Subscribe | SPC020/2005: 20060407, EXPIRES: 20191021 | ||||||||||||||||||||||||||
| C/GB05/031 | United Kingdom | ► Subscribe | PRODUCT NAME: CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT OR COMPLEX THEREOF; REGISTERED: UK EU/1/04/292/001 20041022; UK EU/1/04/292/002 20041022; UK EU/1/04/292/003 20041022; UK EU/1/04/292/004 20041022; UK EU/1/04/292/005 20041022; UK EU/1/04/292/006 20041022; UK EU/1/04/292/007 20041022; UK EU/1/04/292/008 20041022; UK EU/1/04/292/009 20041022; UK EU/1/04/292/010 20041022; UK EU/1/04/292/011 20041022; UK EU/1/04/292/012 20041022; UK EU/1/04/293/001 20041022; UK EU/1/04/293/002 20041022; UK EU/1/04/293/003 20041022; UK EU/1/04/293/004 20041022; UK EU/1/04/293/005 20041022; UK EU/1/04/293/006 20041022; UK EU/1/04/293/007 20041022; UK EU/1/04/293/008 20041022; UK EU/1/04/293/009 200410 | ||||||||||||||||||||||||||
| 182 | Luxembourg | ► Subscribe | 91182, EXPIRES: 20191022 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,668 others who get our Drug Patent Expiration Alerts:
